Mr. Hugh MacNaught reports

ENHANCED DESIGN BREAKTHROUGH MAKES VENTRIPOINT'S VMS+ EVEN SIMPLER TO USE

Ventripoint Diagnostics Ltd. has released a significant upgrade to the design and function of its whole-heart analysis system (VMS+3.2), which accelerates imaging, analysis and ease of use at the point of care.

The new design allows immediate calibration by technicians with existing ultrasound equipment to more quickly generate 2-D (two-dimensional) ultrasound images, which the VMS+3.2 turns into a high-definition three-dimensional heart model. The upgraded system also includes an improved three-dimensional visualization tool, which speeds up and facilitates the analysis of three-dimensional ultrasound exams.

VMS+3.2 release improves the ease-of-use of 2-D and 3-D echocardiogram procedures for sonographers, cardiologists and caregivers, assuring seamless integration of Ventripoint technology into patient-care workflow and standard of care. In a busy echocardiography unit, reducing the time for a procedure without compromising the quality of the results is a constant challenge and the VMS+3.2 will be appreciated for these innovations.

"We are constantly improving the design of our system, to generate efficiencies and better outcomes," said Ventripoint's interim chief executive officer Hugh MacNaught. "This is a best-in-class diagnostic tool that allows enhanced echocardiograms of infants and adults to be available faster and at less cost than a cardiac MRI, with equivalent structural and functional results."

The new design removes the magnet from the probe-tracking system and so it is now immune to environments where magnetic fields are present and is no longer a concern for implanted patient medical devices, such as pacemakers and other cardiac devices, where magnets can be disruptive. The company intends to submit to regulatory agencies for the removal of this limitation on the VMS+ system.

Ventripoint's technology is now being used in leading hospitals in Europe, the United Kingdom, Canada, China and the United States as an alternative to traditional MRI heart scans. These users will be offered the VMS+3.2 upgrade for a fee and future sales will be of the VMS+3.2 version. The company is now focused on expanding the user base in hospitals and clinics worldwide.

The company has a world-class board of clinical advisers who continue to provide ideas for design improvements, which are continuing. The company expects to announce additional enhancements in 2024, which will require regulatory approvals and enable VMS+ to be used with a wider range of patients. It is important to note that these future upgrades are software improvements, which can be seamlessly integrated into existing and new VMS+ units.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide its future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

We seek Safe Harbor.